The story of Sildenafil presents a interesting case for stakeholders in the pharmaceutical sector. While initially a tremendous success, generating vast sums, the patent expiration and the subsequent entry of off-brand competitors have significantly affected income. This poses questions about the long-term viability of similar medication project… Read More